- As on November 18, 2019, the Board of Consort Medical Plc announced that they have agreed on the terms of a recommended cash offer from Recipharm, a wholly-owned direct subsidiary of Recipharm AB. Under the proposed agreement, Recipharm will buy each Consort share at a price of GBX 1,010 in cash.
- The group said that the recommended offer represented a premium of 39.1% from Friday (November 15) closing price of GXB 726 and valuing the company at about £505 million on a fully diluted basis and implies an enterprise value of £627 million.
- While writing (before the market close, at 02:13 PM GMT), its shares traded 314 points or 43.25% higher at GBX 1,040.0.
With Bank of England reducing the interest rates to a historic low level, the spotlight is back on diverse investment opportunities.
Amidst this, are you getting worried about these falling interest rates and wondering where to put your money?
Well! Team Kalkine has a solution for you. You still can earn a relatively stable income by putting money in the dividend-paying stocks.
We think it is the perfect time when you should start accumulating selective dividend stocks to beat the low-interest rates, while we provide a tailored offering in view of valuable stock opportunities and any dividend cut backs to be considered amid scenarios including a prolonged market meltdown.